Table 4

Random-effects pooled results: gabapentin vs. placebo.

Outcome

Treatment effect (θ)

95% CI for θ

U-test

(p-value)

τ2

NNT/NNH

(95% CI)


Efficacy

Reduction in 24-hour pain intensity

-1.437

(-2.211; -0.663)

<0.001

0.109

*


Tolerability

Premature study discontinuation due to:

- Lack of efficacy

-1.066

(-2.786; 0.653)

0.224

0

- Adverse events

0.241

(-0.786; 1.267)

0.646

0

63 (30; ∞)

- Other

-0.036

(-1.162; 1.090)

0.950

0

Diarrhoea

0.393

(-0.555; 1.341)

0.416

0

Dizziness

1.833

(0.834; 2.833)

<0.001

0

Headache

1.146

(-0.018; 2.310)

0.054

0

Nausea

0.595

(-0.532; 1.722)

0.301

0

Somnolence

1.582

(0.643; 2.520)

0.001

0


Note:

θ is absolute difference for 24-hour pain intensity.

θ is log-odds ratio for all tolerability analyses.

τ2 is between-study heterogeneity.

NNT/NNH: Number needed to treat, number needed to harm. * NNT was not calculated, due to absence of required binary data on responder rates. NNH was calculated for discontinuation due to adverse events.

Quilici et al. BMC Neurology 2009 9:6   doi:10.1186/1471-2377-9-6

Open Data